

关于诺唯赞新冠抗原检测试剂对于新型突变株检测的包容性说明

Notice

(Vazyme reagents inclusiveness on detecting variants of the SARS-CoV-2 Virus)

鉴于新冠病毒的频繁变异引起人们对于抗原检测试剂有效性的担忧，诺唯赞研发团队持续关注病毒变异情况。对于世界卫生组织最新报告的 Omicron(B.1.1.529)新冠病毒突变毒株，经生物信息学分析，我司的新冠抗原检测试剂盒 SARS-CoV-2 Antigen Detection Kit (Colloidal Gold-Based)可有效检出，其检测性能实验室验证试验尚在进行中。

经过前期检测结果分析，诺唯赞新冠抗原检测试剂盒 SARS-CoV-2 Antigen Detection Kit (Colloidal Gold-Based)对已报道的 Alpha(英国 B1.1.7)、Beta (南非 B.1.351)、Gamma (巴西 P.1)、Delta (印度 B.1.617.2、AY.1, AY.2, AY.3)、Zeta (巴西 P.2)、Eta (英国/尼日利亚 B.1.525)、Iota (美国 B.1.526)、Kappa (印度 B.1.617.1)、Lambda (秘鲁 C.37)等新冠病毒突变株均能覆盖，不会发生漏检。我司将持续保持相关信息的更新与公布。

The frequent mutations of the SARS-CoV-2 virus made people concerned much about the effectiveness of the current antigen detection reagents. The R&D team of Vazyme has always maintained continuous attention. Based on analysis of biological information, SARS-CoV-2 Antigen Detection Kit (Colloidal Gold-based) of Vazyme could detect Omicron(B.1.1.529) that currently reported by WHO. And laboratory validation is still underway.

Analysis by the previous test results, the sensitivity and specificity of detection on Alpha(UK B1.1.7), Beta (South Africa B.1.351), Gamma (Brazil P.1), Delta (India B.1.617.2, AY.1, Ay.2, Ay.3), Zeta (Brazil P.2), Eta (England/Nigeria B.1.525), Iota(United States B.1.526), Kappa (India B.1.617.1), Lambda (Peru C.37).etc. could be guaranteed for SARS-CoV-2 Antigen Assay Kit (Colloidal Gold). Our company will continue to update and publish relevant information.

南京诺唯赞医疗科技有限公司

2021年11月29日

Nanjing Vazyme Medical Technology Co., Ltd.

29.11.2021

